预约演示
更新于：2026-09-04
Levalbuterol hydrochloride
盐酸左沙丁胺醇
更新于：2026-09-04
概要
基本信息
药物类型 小分子化药 |
别名 NSC-759255、Xopenex、丽舒同 + [1] |
作用方式 激动剂 |
作用机制 β2-adrenergic receptor激动剂(β2-肾上腺素能受体激动剂) |
治疗领域 |
非在研适应症- |
在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1999-03-25), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C13H22ClNO3 |
InChIKeyOWNWYCOLFIFTLK-YDALLXLXSA-N |
CAS号50293-90-8 |
关联
10
项与 盐酸左沙丁胺醇 相关的临床试验NCT05173584
Is Levalbuterol an Effective Treatment With Less Cardiac Side Effects Than Albuterol in Hyperkalemia Patients: A Randomized-controlled Clinical Trial Protocol.
NCT03952286
ED-Initiated School-based Asthma Medication Supervision
NCT02802111
Change in Oxygen Consumption Following Inhalation of Albuterol in Comparison With Levalbuterol in Healthy Adult Volunteers
100 项与 盐酸左沙丁胺醇 相关的临床结果
登录后查看更多信息
100 项与 盐酸左沙丁胺醇 相关的转化医学
登录后查看更多信息
100 项与 盐酸左沙丁胺醇 相关的专利（医药）
登录后查看更多信息
397
项与 盐酸左沙丁胺醇 相关的文献（医药）2025-08-03JOURNAL OF ASTHMA
Safety and effectiveness of mepolizumab in adult patients with severe asthma with an eosinophilic phenotype from India: a Phase IV, open-label, single-arm, 24-week study (PRISM)
Article
作者: Swarnakar, Rajesh ; Adsule, Samir ; Meshram, Priti ; Hegde, Rashmi ; Maturu, Venkata Nagarjuna ; Deb, Pooja ; Gupta, Disha
OBJECTIVE:
Existing mepolizumab trials have excluded patients with severe asthma with an eosinophilic phenotype (SAEP) from India. This study (NCT04276233) investigated the safety and effectiveness of mepolizumab in Indian adults with SAEP.
METHODS:
Multi-center, open-label, single-arm, interventional study; patients received 100 mg mepolizumab subcutaneously every four weeks for 24 weeks. Primary endpoint: incidence of adverse events (AEs), serious AEs (SAEs), and AEs of special interest (AESIs). Secondary endpoints: clinically significant exacerbation (CSEs) frequency (including exacerbations requiring hospitalization); change from baseline to Week 24 in forced expiratory volume/second (FEV1), peak expiratory flow (PEF), and Asthma Control Questionnaire (ACQ-5) scores.
RESULTS:
Overall, 100 patients received ≥1 mepolizumab dose. Baseline characteristics: female, 51.0%; mean (standard deviation [SD]) age, 44.8 (12.0) years; mean (SD) body mass index, 24.4 (4.7) kg/m2. On-treatment AEs and SAEs were reported by 18.0% and 3.0% of patients, respectively; regarding AESIs, 5.0% reported infection and 2.0% reported systemic reaction. One fatal event occurred (unrelated to mepolizumab). CSEs were reported by 8.0% of patients; 2.0% had an exacerbation requiring hospitalization. Least squares (LS) mean change (95% confidence interval) in pre- and post-bronchodilator FEV1 and PEF by Week 24 was 0.081 L (-0.05, 0.21; p = 0.231), 0.055 L (-0.06, 0.17; p = 0.325), and 13.67 L/min (3.08, 24.25; p = 0.012), respectively. By Week 24, ACQ-5 scores had significantly improved (LS mean change [standard error]: -0.69 [0.121]; p < 0.001).
CONCLUSIONS:
Mepolizumab was well tolerated in Indian adults with SAEP and improved asthma control and health-related quality of life.
2025-06-01Drug Testing and Analysis
Beta2‐adrenergic agonist salbutamol exhibits enantioselective disposition in skeletal muscle of lean young men following oral administration
Article
作者: Hostrup, Morten ; Jacobson, Glenn A. ; Narkowicz, Christian K. ; Nichols, David S. ; Eibye, Kasper ; Jessen, Søren
Abstract:
Salbutamol is a common short‐acting beta2‐adrenergic agonist used in treatment of asthma and exercise‐induced bronchoconstriction but also possesses anabolic and metabolic actions in skeletal muscle. As a chiral compound, salbutamol is a racemic 1:1 mixture of two enantiomers, (R)‐salbutamol and (S)‐salbutamol, which exhibit divergent pharmacokinetic and pharmacodynamic actions. Despite salbutamol being available for decades, information on the enantioselective disposition of salbutamol enantiomers in human skeletal muscle is absent. In this study, we determined concentrations of (R)‐salbutamol and (S)‐salbutamol by UHPLC–MS/MS in arterial plasma and vastus lateralis muscle samples from 12 lean young men 2½ and 7 h following ingestion of 24 mg oral salbutamol. Mean (range) arterial plasma concentrations were 10‐fold higher (p < 0.001) for (S)‐salbutamol than (R)‐salbutamol, being 33(9–62) and 49(30–84) ng·mL−1 for (S)‐salbutamol and 4 (1‐6) and 4 (2‐5) ng·mL−1 for (R)‐salbutamol 2½ and 7 h following administration, respectively, reflecting faster elimination of the (R)‐enantiomer. Mean (range) muscle concentrations were higher (p < 0.001) for (S)‐salbutamol than (R)‐salbutamol 2½ h (0.17 [0.1–0.26] vs. 0.04 [0.02–0.06]) and 7 h (0.31 [0.21–0.46] vs. 0.06 [0.04–0.12] ng·mgd.w.−1) after administration. However, muscle:plasma partition coefficient was two‐fold higher (p < 0.001) for (R)‐salbutamol than (S)‐salbutamol 7 h following administration. These observations demonstrate that oral salbutamol exhibits enantioselective disposition in systemic circulation and muscle favoring the (S)‐enantiomer but with higher relative partitioning of the (R)‐enantiomer in skeletal muscle. Furthermore, the concentration‐time profiles of salbutamol enantiomers are different in skeletal muscle and systemic circulation following oral ingestion. These findings have implications for the application of chiral switch (R)‐salbutamol in doping control.
2025-05-01ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
Exacerbation burden in patients treated as intermittent or mild-persistent asthma using short-acting β2-agonist rescue
Article
作者: Gandhi, Hitesh N ; Lugogo, Njira L ; Tkacz, Joseph P ; Lanz, Miguel J ; Gilbert, Ileen A
BACKGROUND:
Most people in the United States with asthma use therapies for intermittent/mild-persistent disease; however, exacerbations and death occur in patients with infrequent symptoms or labeled as mild asthma.
OBJECTIVE:
To evaluate relationships between short-acting β2-agonist (SABA) use, exacerbations, and maintenance adherence in intermittent/mild-persistent asthma.
METHODS:
Retrospective cohort study using US Merative MarketScan administrative claims (January 2010 to December 2017) for patients aged 12 years or older treated as intermittent/mild-persistent asthma. Patients were indexed on a random SABA claim, with 12 months continuous enrollment pre- and post-index. Post-index SABA groups were defined as low (index fill only), medium (2-3 fills), and high (≥4 fills). Severe exacerbations were compared within the treatment, SABA fill, and adherence (medication possession ratio) groups through unadjusted comparison of proportions, χ2, and odds ratios (OR [95% CI]); P less than or equal to .05.
RESULTS:
A total of 533,679 patients were included: 68.1% female; mean age (SD) 34.6 (18.3) years; 70.0% intermittent (SABA only) and 30.0% mild-persistent (8.6% low-dose inhaled corticosteroid [ICS]; 21.4% leukotriene modifier [LM]). The proportion of patients with high SABA fills differed among the treatments: SABA only (14.8%), low-dose ICS (37.0%), and LM (25.5%) (P < .001). The proportion experiencing 1 or more exacerbations was higher in SABA only (61.2%) vs low-dose ICS (40.4%) or LM (50.4%): OR (95% CI) 2.32 (2.28-2.37) and 1.55 (1.53-1.57), respectively (both P < .001). The medication possession ratio was less than 50% in 59.3% of patients with mild-persistent asthma; however, adherence was only related to exacerbations in the high SABA group.
CONCLUSION:
Patients treated as intermittent/mild-persistent asthma rely on SABA and experience exacerbations. Shifting from SABA only to an anti-inflammatory rescue therapy could decrease morbidity.
100 项与 盐酸左沙丁胺醇 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 气道阻塞 | 中国 | 2019-09-26 | |
| 支气管痉挛 | 美国 | 1999-03-25 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 100 | 築築襯夢鹹襯醖齋蓋糧(願醖鹹積齋遞範襯簾鏇) = 鑰餘築餘構廠構網鏇構 築構蓋獵壓選醖鏇醖淵 (淵窪範願簾鑰簾範構窪 ) | 积极 | 2025-12-08 | |||
築築襯夢鹹襯醖齋蓋糧(願醖鹹積齋遞範襯簾鏇) = 鑰窪蓋遞糧鹽願簾繭鹹 築構蓋獵壓選醖鏇醖淵 (淵窪範願簾鑰簾範構窪 ) | |||||||
临床4期 | 13 | budesonide+prednisolone+albuterol sulfate (ED-Dispensing With Home and School Supervision) | 壓顧範製製願範鑰鏇憲 = 範簾醖餘觸壓製鏇窪範 憲選選構廠鑰餘齋簾獵 (製獵遞積衊糧簾觸襯憲, 艱築壓繭衊積鏇夢襯繭 ~ 齋觸糧淵觸願壓願顧網) 更多 | - | 2025-11-19 | ||
budesonide+prednisolone+albuterol sulfate (ED-Dispensing With Home Supervision) | 壓顧範製製願範鑰鏇憲 = 醖鹹糧顧觸構築鹹壓簾 憲選選構廠鑰餘齋簾獵 (製獵遞積衊糧簾觸襯憲, 顧艱壓膚鏇衊鹹簾構糧 ~ 齋壓網膚窪選選積構繭) 更多 | ||||||
N/A | 24 | (Albuterol 5 mg First, Then Levalbuterol 2.5 mg) | 艱淵夢繭壓壓顧製顧衊(夢鹽醖築積構蓋膚獵築) = 糧網艱餘襯遞顧憲壓夢 襯鏇齋範簾醖醖窪壓繭 (廠齋鹹網構膚觸蓋獵淵, 蓋憲醖鑰製繭遞積壓餘 ~ 簾蓋鑰衊選鏇衊構遞觸) 更多 | - | 2020-10-28 | ||
(Levalbuterol 2.5 mg First, Then Albuterol 5 mg) | 艱淵夢繭壓壓顧製顧衊(夢鹽醖築積構蓋膚獵築) = 獵淵構築艱構構醖製廠 襯鏇齋範簾醖醖窪壓繭 (廠齋鹹網構膚觸蓋獵淵, 鹽製鑰窪餘構顧衊壓獵 ~ 壓簾鏇範積襯積膚積醖) 更多 | ||||||
N/A | 56 | Spirometry test+Levalbuterol (COPD Assessment and Management Recommendations) | 襯構餘壓衊醖襯鬱衊淵 = 網艱醖築範製窪遞選糧 蓋窪淵襯膚膚選簾遞觸 (積顧構鬱構選壓鑰繭餘, 構製範遞鑰築鑰積齋構 ~ 製壓鹽廠鏇夢襯積繭淵) 更多 | - | 2019-12-24 | ||
Spirometry test+Levalbuterol (Usual Care) | 襯構餘壓衊醖襯鬱衊淵 = 獵網顧鏇餘願選遞齋繭 蓋窪淵襯膚膚選簾遞觸 (積顧構鬱構選壓鑰繭餘, 夢繭鑰艱餘衊鹽餘獵獵 ~ 餘醖蓋壓選餘獵糧膚齋) 更多 | ||||||
临床4期 | 89 | 鹹淵夢積醖選齋積願築(鏇窪遞艱淵鏇鬱製製構) = 製淵窪願憲壓醖淵構鏇 簾窪餘鏇淵衊蓋鹽衊廠 (築醖鏇鬱繭簾築襯壓選, 5.4) 更多 | - | 2015-10-23 | |||
临床4期 | 101 | (Levalbuterol (Xopenex)) | 糧觸築構願範壓築襯繭(餘膚願壓願廠構壓淵製) = 齋醖鬱鹹顧製餘鬱醖廠 繭窪鬱顧觸膚觸製餘醖 (範廠餘廠構鏇齋製獵網, 餘憲願選範齋淵廠窪築 ~ 鬱醖廠窪獵構鑰齋膚製) 更多 | - | 2011-08-16 | ||
Albuterol (Albuterol) | 糧觸築構願範壓築襯繭(餘膚願壓願廠構壓淵製) = 窪鏇餘膚廠齋網簾願廠 繭窪鬱顧觸膚觸製餘醖 (範廠餘廠構鏇齋製獵網, 鏇繭鹽簾鏇鏇觸構願蓋 ~ 齋糧齋構觸憲網遞製廠) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用